These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37909320)
1. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients. Schreiber H; Hipp J; Roßnagel F; Moritz C Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320 [TBL] [Abstract][Full Text] [Related]
2. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664 [TBL] [Abstract][Full Text] [Related]
3. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice. Mitsikostas D; Bakirtzis C; Nikolaidis I; Tsimourtou V; Kountra P; Matsi S; Papadimitriou A Neurodegener Dis Manag; 2022 Dec; 12(6):311-322. PubMed ID: 36178000 [TBL] [Abstract][Full Text] [Related]
4. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis]. Boyko AN; Alifirova VM Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Hellwig K; Thiel S; Haben S; Ciplea AI; Kurzeja A Neurodegener Dis Manag; 2023 Aug; 13(4):223-234. PubMed ID: 37382065 [TBL] [Abstract][Full Text] [Related]
8. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate. Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757 [TBL] [Abstract][Full Text] [Related]
9. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426 [TBL] [Abstract][Full Text] [Related]
10. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon. Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576 [TBL] [Abstract][Full Text] [Related]
11. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S; Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058 [TBL] [Abstract][Full Text] [Related]
12. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
13. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. Ziemssen T; Calabrese P; Penner IK; Apfel R J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926 [TBL] [Abstract][Full Text] [Related]
14. Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S Mult Scler Relat Disord; 2020 May; 40():101957. PubMed ID: 32028117 [TBL] [Abstract][Full Text] [Related]
15. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922 [TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329 [TBL] [Abstract][Full Text] [Related]
17. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F; J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008 [TBL] [Abstract][Full Text] [Related]